Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.39 |
| ▸ | MGLL | Q99685 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919121 | 0.91 | HCRTR1 (0.40) | CFTRSMN1; SMN2NTRK1MGLLHCRTR1 | |
| SCHEMBL2917820 | 0.89 | MGLL (0.48) | CFTRMGLLKDM1ACCKAR | |
| SCHEMBL2919855 | 0.88 | MGLL (0.50) | CFTRNTRK1MGLLCCKAR | |
| SCHEMBL5270015 | 0.86 | NTRK1 (0.43) | NTRK1MGLLMEN1KMT2AKDM1A | |
| SCHEMBL2919136 | 0.86 | NTRK1 (0.45) | CFTRNTRK1MGLLCCKAR | |
| SCHEMBL5271833 | 0.86 | NTRK1 (0.48) | NTRK1MEN1KMT2AKDM1A | |
| SCHEMBL5270595 | 0.86 | MEN1 (0.43) | NTRK1MGLLMEN1KMT2AKDM1A | |
| SCHEMBL2921813 | 0.85 | NTRK1 (0.51) | NTRK1MGLLMEN1KMT2AKDM1A | |
| SCHEMBL2916328 | 0.85 | BRD4 (0.41) | NTRK1MGLLHCRTR1HCRTR2 | |
| SCHEMBL13637539 | 0.85 | MALT1 (0.45) | CFTRSMN1; SMN2MGLLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CFTR 1992/4885SMN1; SMN2 3778/4885NTRK1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.